This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NVP-HSP990
Description: NVP-HSP990 is a small molecule Heat shock protein 90 (HSP90) inhibitor. HSP90 is a therapeutic target for the treatment of cancer. Proteins are the mainstay of structural and signaling elements of all cells. Hsp90 functions to stabilize and maintain the equilibrium of proteins in the cancer cell, thereby allowing a cancer cell to survive despite an abundance of misfolded and unstable proteins.
Deal Structure: Vemalis will receive from Novartis milestone payments as the compound progresses through development, and royalty payments upon commercialisation.
Partners: Vernalis Group plc
Additional information available to subscribers only: